JHJan Hrbáček

Jan Hrbáček

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jan Hrbáček has a total of 41 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    External validation of extended prostate biopsy nomogram

    by Jan Hrbáček, Ivo Minárik, Tomáš Sieger, Marek Babjuk

    Historical nomograms for the prediction of cancer on prostate biopsy, developed in the sextant biopsy era are no more accurate today. The aim of this study was an independent external validation of a 10-core biopsy nomogram by Chun et al. (2007). A total of 322 patients who presented for their initial biopsy in a tertiary care center and had all the necessary data available were included in the retrospective analysis. To validate the nomogram, receiver operator characteristic (ROC) curves and calibration plots were constructed. Area under the ROC curve calculated for our data using the nomogram was 0.773, similar to that reported originally. However, the nomogram systematically overestimated prostate cancer risk, which, for our data, could be resolved by subtracting 24 points from the total number of points of the nomogram. The nomogram yielded overall good predictive accuracy as measured by the area under the ROC curve, but it systematically overestimated PC probability in individual patients. However, we showed how the nomogram could easily be adapted to our patient sample, resolving the bias issue.

  • Impact of perioperative chemotherapy on survival in patients with advanced primary urethral cancer: Results of the international collaboration on primary urethral carcinoma.

    by Georgios Gakis, Todd Matthew Morgan, Siamak Daneshmand, Kirk A. Keegan, Harras B Zaid, Jan Hrbacek, Bedeir Ali-El-Dein, Rebecca Helen Clayman, Lars Weissbach, Tilman Todenhoefer, et al.

    4587 Background: The present analysis aims to investigate the prognostic benefit of perioperative chemotherapy in patients undergoing surgery for primary urethral carcinoma. Methods: A total of 124 patients (86 men, 38 women) who were diagnosed with primary urethral carcinoma in ten tertiary international academic centers between 1993 and 2012, underwent surgery for primary treatment. Platinum-based neoadjuvant and adjuvant chemotherapy was administered in 18 (15%) and 21 (17%) patients, respectively. Kaplan-Meier analysis with log-rank testing was used to investigate the impact of perioperative chemotherapy on progression-free (PFS) and overall survival (OS). The median follow-up was 20 months (mean: 32 months; IQR: 4-48). Results: Median age at surgery was 67 years (IQR: 53-74). Receipt of neoadjuvant chemotherapy was associated with clinically node-positive tumor stage (cN+; p=0.009). Conversely, delivery of adjuvant chemotherapy was associated with locally advanced primary tumors (≥cT3; p=0.003). No further significant associations were found between perioperative chemotherapy and age, gender, tumor location (proximal vs. distal), underlying histology, tumor grade and use of palliative therapy. The 3-year PFS/3-year OS for patients with cN+-stage disease who underwent neoadjuvant chemotherapy was 40%/100%, compared to 0%/29% for no neoadjuvant chemotherapy (p=0.043 and p=0.034, respectively). By contrast, the 3-year PFS/3-year OS for patients with ≥cT3-stage disease who received adjuvant chemotherapy was 23%/46%, versus 20%/53% for no adjuvant chemotherapy (p=0.44 and p=0.20, respectively). The 3-year OS for patients with ≥cT3 and/or cN+ stage disease who received neoadjuvant chemotherapy was 100%, compared to 20% for adjuvant chemotherapy (p=0.031). Conclusions: In this series, patients who received neoadjuvant platinum-based chemotherapy for locally advanced primary urethral carcinoma exhibited improved survival compared to those who underwent immediate surgery and adjuvant chemotherapy.


    • 1 October 2012
      • Vol. 18  (5) , 150-5

    [HIV and male infertility disorders].

    by Jiří Heráček, Jan Hrbáček, Vladimír Sobotka, Ivan Kolombo, Michael Urban

    This review article provides information on the impact of HIV-1 on male reproductive functions. HIV-positive patients of reproductive age with now a long-term prognosis may wish to have children. If only one partner is infected, natural conception brings the risk of virus transmission. The article reviews the reproduction possibilities for HIV-positive couples and explains the ways to reduce the risk of transmitting the virus to the healthy partner or a child. Assisted reproduction techniques, especially intrauterine insemination, in vitro fertilization and intracytoplasmic sperm injection in combination with sperm washing can successfully reduce the risk of HIV transmission. Current trends and dilemmas of infertility treatment in HIV-positive couples are discussed.

  • HPV persistence and its oncogenic role in prostate tumors

    by Ruth Tachezy, Jan Hrbacek, Jiri Heracek, Martina Salakova, Jana Smahelova, Viera Ludvikova, Alexandr Svec, Michael Urban, Eva Hamsikova

    HPV has carcinogenic effects at several anatomical sites in women and men. Whether the presence of HPV in the genitourinary tract of men is associated with a higher prostate cancer risk has been a matter of research for a long-time and the results are still not fully conclusive. Similarly, the question of the reservoir of HPV infection in men is not clearly resolved. HPV DNA presence and types were evaluated by means of polymerase chain reaction in the tissue of 146 patients with benign prostate hyperplasia and prostate cancer. HPV-specific antibodies were analyzed by enzyme-linked immunosorbent assay in the sera of all patients and 172 controls. In addition, 256 biopsies taken from non-tumorous tissues were analyzed. No statistically significant differences were observed in HPV DNA prevalence between patients with benign prostate hyperplasia (2%) and patients with prostatic cancer (2%; P = 1.000). The seropositivity rates did not differ significantly between groups of subjects except for antibodies against HPV 6 VLPs which were found more often in prostate cancer patients (adjusted P = 0.018). Similarly, no difference in the seroprevalence rates for HPV 16 E6 and/or E7 oncoproteins between groups of patients and healthy controls was detected. The overall HPV prevalence in 256 healthy tissue samples was 4%. The results indicate that HPV infection is not associated with prostate oncogenesis in men. However, they imply that multiple tissues of the male genitourinary tract may be important reservoirs for the transmission of some HPV types. J. Med. Virol. 84:1636–1645, 2012.


  • Open Access

    Serum antibodies against genitourinary infectious agents in prostate cancer and benign prostate hyperplasia patients: a case-control study

    by Jan Hrbacek, Michael Urban, Eva Hamsikova, Ruth Tachezy, Vaclav Eis, Marek Brabec, Jiri Heracek

    Background: Infection plays a role in the pathogenesis of many human malignancies. Whether prostate cancer (PCa) - an important health issue in the aging male population in the Western world - belongs to these conditions has been a matter of research since the 1970 s. Persistent serum antibodies are a proof of present or past infection. The aim of this study was to compare serum antibodies against genitourinary infectious agents between PCa patients and controls with benign prostate hyperplasia (BPH). We hypothesized that elevated serum antibody levels or higher seroprevalence in PCa patients would suggest an association of genitourinary infection in patient history and elevated PCa risk. Methods: A total of 434 males who had undergone open prostate surgery in a single institution were included in the study: 329 PCa patients and 105 controls with BPH. The subjects' serum samples were analysed by means of enzyme-linked immunosorbent assay, complement fixation test and indirect immunofluorescence for the presence of antibodies against common genitourinary infectious agents: human papillomavirus (HPV) 6, 11, 16, 18, 31 and 33, herpes simplex virus (HSV) 1 and 2, human cytomegalovirus (CMV), Chlamydia trachomatis, Mycoplasma hominis, Ureaplasma urealyticum, Neisseria gonorrhoeae and Treponema pallidum. Antibody seroprevalence and mean serum antibody levels were compared between cases and controls. Tumour grade and stage were correlated with serological findings. Results: PCa patients were more likely to harbour antibodies against Ureaplasma urealyticum (odds ratio (OR) 2.06; 95% confidence interval (CI) 1.08-4.28). Men with BPH were more often seropositive for HPV 18 and Chlamydia trachomatis (OR 0.23; 95% CI 0.09-0.61 and OR 0.45; 95% CI 0.21-0.99, respectively) and had higher mean serum CMV antibody levels than PCa patients (p = 0.0004). Among PCa patients, antibodies against HPV 6 were associated with a higher Gleason score (p = 0.0305). Conclusions: Antibody seropositivity against the analyzed pathogens with the exception of Ureaplasma does not seem to be a risk factor for PCa pathogenesis. The presence or higher levels of serum antibodies against the genitourinary pathogens studied were not consistently associated with PCa. Serostatus was not a predictor of disease stage in the studied population.


    • 1 January 2010
      • Vol. 149  (3) , 115-9

    [Urologic complications of HIV infection].

    by Jan Hrbácek, Pavel Konopásek, Václav Eis, Eva Hamsíková, Ruth Tachezy, Jan Pokorný, Karim El-Balouly, Michael Urban, Jirí Herácek

    As life expectancy of patients infected by Human Immunodeficiency Virus (HIV) has prolonged, they are treated by physicians of different specialities. This article focuses on urologic complications of HIV infection. Urinary tract infections in HIV positive patients are more frequent than in otherwise healthy individuals and less common microorganisms can be involved. Sexually transmitted diseases are a commonplace. Certain malignancies of the genitourinary tract are more often diagnosed in HIV positive than in HIV negative population. Impairment of kidney function is usually caused by HIV-associated nephropathy. Acute renal failure can also occur. Indinavir causes urinary stones formation. Male circumcision is an effective method of HIV transmission prevention.


  • Open Access

    Prostate cancer incidence, diagnostic and treatment in HIV-positive patients

    by Jan Hrbáček, Jiří Heráček, Václav Eis, Eva Hamšíková, Ruth Tachezy, Michael Urban

    C?lem p?ehledov?ho ?l?nku je shrnout dosavadn? publikace, kter? se zab?vaj? v?skytem, diagnostikou a l??bou karcinomu prostaty v HIV pozitivn? populaci. Relevantn? publikace jsme vybrali na z?klad? re?er?e v datab?zi Medline.Zaveden? vysoce ak...